Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $83.0 million.

  • Indivior Pharmaceuticals' Cost of Revenue rose 2575.76% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.0 million, marking a year-over-year decrease of 255.32%. This contributed to the annual value of $231.0 million for FY2024, which is 3275.86% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Cost of Revenue of $83.0 million as of Q3 2025, which was up 2575.76% from $52.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Cost of Revenue's 5-year high stood at $83.0 million during Q3 2025, with a 5-year trough of $38.0 million in Q2 2022.
  • For the 4-year period, Indivior Pharmaceuticals' Cost of Revenue averaged around $51.4 million, with its median value being $48.0 million (2023).
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Cost of Revenue soared by 5800.0% in 2024, and later plummeted by 3417.72% in 2025.
  • Indivior Pharmaceuticals' Cost of Revenue (Quarter) stood at $43.0 million in 2022, then rose by 20.93% to $52.0 million in 2023, then dropped by 3.85% to $50.0 million in 2024, then surged by 66.0% to $83.0 million in 2025.
  • Its last three reported values are $83.0 million in Q3 2025, $52.0 million for Q2 2025, and $44.0 million during Q1 2025.